Predictors of functional deterioration in Chinese patients with Psoriatic arthritis: a longitudinal study

Abstract

BackgroundPsoriatic arthritis (PsA) disease activities at baseline may determine physical function over time. There is no longitudinal data on course of physical function in PsA patients from Asia. We aim to describe variables associated with a deterioration of physical function in PsA in Chinese over a 6-year period.Methods125 consecutive patients with PsA fulfilled the CASPAR criteria from a rheumatology outpatient center were recruited to give sociodemographic and clinical data in 2006 to 2008. Follow up interviews were conducted in 2012 to 2013 to assess physical function using Health Assessment Questionnaire (HAQ). Regression models were constructed to determine baseline variables that predict physical function on follow up.ResultsA total of 97 patients completed the follow up survey, with mean follow up time of 6.2 (±0.7) years, response rate 77.6%. PsA patients had poor physical function and health related quality of life (HRQoL) compared to normal population. There were 33% who improved in disability status and 41.2% had persistent minimal disability by HAQ categories (HAQ 0–0.49) over time. There were 14.4% of the patients who had persistent moderate disability (HAQ 0.5-1.50) and 10.3% had deterioration in disability status. There were 17.5% of patients who had deterioration in physical function as defined by an increment of HAQ score of more than 0.2 at follow up survey. Age, physical function at baseline and the number of damaged joint were significantly related HAQ at follow up.ConclusionChinese patients with PsA had had poor physical function and quality of life. One fifth of patient experienced deterioration of physical function over time. Joint damage and baseline physical function were important factors associated with poor physical function in PsA over time.

Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial

“…According to consensus findings from an international task force, the primary goal of treating individuals with PsA is to "maximize long-term health-related quality of life and social participation through control of signs and symptoms, prevention of structural damage, normalization or preservation of function, avoidance of toxicities, and minimization of comorbidities" 19 . Thus, it is noteworthy that IV GOL can effectively treat these diverse aspects of PsA, including inhibition of radiographic progression, which is particularly consequential for longer-term outcomes of patient function and disability 20,21 . Further analyses will extend radiographic evaluation of IV GOL in patients with PsA through 1 year to address a limitation of the current report (i.e., relatively short duration of followup in this chronic disease).…”

Classification and Outcome Measures for Psoriatic Arthritis

“…It affects young adults of working age, with typical age of onset in the 30–50s ( 1 ). Destructive changes in bones can develop early resulting in joint damage and loss of function ( 2 – 4 ). Furthermore, higher inflammatory burden over time may lead to accelerated atherosclerosis, increased cardiovascular morbidity ( 5 , 6 ), and possible early mortality for those with severe disease ( 7 , 8 ).…”

Clinical characteristics and comorbidities of psoriatic arthritis (PsA) in Hong Kong

“…The prevalence of psoriatic disease is reported to be 3.15% in the United States [2]. Very often, it progresses rapidly to permanent joint destruction, leading to functional impairment and deteriorated quality of life in patients [3]. With the launch of new biologic agents for psoriatic diseases in the past few years, the awareness among physicians and the general public of this nasty condition is increasing, which has resulted in an overall increase in the number of diagnosed cases of psoriatic disease [4,5].…”

“…With the launch of new biologic agents for psoriatic diseases in the past few years, the awareness among physicians and the general public of this nasty condition is increasing, which has resulted in an overall increase in the number of diagnosed cases of psoriatic disease [4,5]. However, there is little updated epidemiological information on PsA in Hong Kong [1,3]. The majority of local data is based on a study of 127 Chinese PsA patients conducted over a decade ago in which the sample size was relatively small [1,3].…”

“…However, there is little updated epidemiological information on PsA in Hong Kong [1,3]. The majority of local data is based on a study of 127 Chinese PsA patients conducted over a decade ago in which the sample size was relatively small [1,3]. Thus, more PsA data is definitely needed.…”